Skip to content
10-Q

Quarterly Report

IGM Biosciences, Inc.

0000950170-24-096639

← back to feed
Filed
Aug 14, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Current Liabilities Q2 2024 · Jun 30, 2024 $37.66M
Current Liabilities Q2 2024 · Dec 31, 2023 $42.48M
Total Liabilities Q2 2024 · Jun 30, 2024 $214.14M
Total Liabilities Q2 2024 · Dec 31, 2023 $220.18M
Current Assets Q2 2024 · Jun 30, 2024 $266.02M
Current Assets Q2 2024 · Dec 31, 2023 $347.6M
Total Assets Q2 2024 · Jun 30, 2024 $336.5M
Total Assets Q2 2024 · Dec 31, 2023 $423.41M
Cash And Equivalents Q2 2024 · Dec 31, 2023 $112.52M
Cash And Equivalents Q2 2024 · Jun 30, 2023 $150.7M
Shares Diluted Q2 2024 · Jun 30, 2023 45.12M sh
Shares Diluted Q2 2024 · Jun 30, 2023 44.8M sh
Capex Q2 2024 · Jun 30, 2023 $7.85M
Operating Cash Flow Q2 2024 · Jun 30, 2023 −$104.1M
Stockholders Equity Q2 2024 · Jun 30, 2023 $258.61M
Stockholders Equity Q2 2024 · Mar 31, 2023 $239.43M
Stockholders Equity Q2 2024 · Dec 31, 2022 $287.26M
Eps Diluted Q2 2024 · Jun 30, 2023 −$1.43
Eps Diluted Q2 2024 · Jun 30, 2023 −$2.76
Eps Basic Q2 2024 · Jun 30, 2023 −$1.43
Eps Basic Q2 2024 · Jun 30, 2023 −$2.76
Sga Expense Q2 2024 · Jun 30, 2023 $12.98M
Sga Expense Q2 2024 · Jun 30, 2023 $25.99M
Rd Expense Q2 2024 · Jun 30, 2023 $55.67M
Rd Expense Q2 2024 · Jun 30, 2023 $106.57M
Net Income Q2 2024 · Jun 30, 2023 −$64.42M
Net Income Q2 2024 · Jun 30, 2023 −$123.73M
Net Income Q2 2024 · Mar 31, 2023 −$59.31M
Operating Income Q2 2024 · Jun 30, 2023 −$68.21M
Operating Income Q2 2024 · Jun 30, 2023 −$131.58M